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Our case series showed that uncomplicated Yarrowia lipolytica fungemia might be treated with catheter removal alone. The Vi-
tek 2 YST identification (ID) card system, matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-
TOFMS), and internal transcribed spacer and 25S nuclear ribosomal DNA (nrDNA) gene sequencing provided reliable identifi-
cation. All isolates had lowMICs to voriconazole, echinocandins, and amphotericin B.
Agrowing number of non-albicans Candida spp. have emergedin recent years as important human pathogens among the
growing, heterogeneous population of immunocompromised
and critically ill patients (1–3). Yarrowia lipolytica (Candida lipo-
lytica) is an ascomycetous yeast found ubiquitously in the envi-
ronment and meat products, including sausages and dairy prod-
ucts, especially cheese (4). It may occasionally be found as a
colonizer in the feces, oropharyngeal swabs, sputa, and skin swabs
of asymptomatic persons (5). Its intense secretory activity is
widely employed in the food, detergent, and pharmaceutical in-
dustries to produce aroma compounds, organic acids, polyalco-
hols, emulsifiers, and surfactants (4, 6, 7). Although Y. lipolytica
was previously considered to be of low virulence, it has been in-
creasingly recognized to cause sporadic cases and nosocomial
clusters of human infections, especially catheter-related suppura-
tive thrombophlebitis and fungemia associated with biofilm for-
mation in immunocompromised or critically ill patients who
experience prolonged hospitalization and who required long-
dwelling intravascular catheterization and broad-spectrum anti-
bacterial agents (5, 8–10). Other forms of clinical disease, includ-
ing noncatheter-related fungemia, traumatic ocular infection, and
acute exacerbation of chronic sinusitis, have also been reported (5,
8, 11). A major limitation of the literature onY. lipolytica infection
is that most studies were case reports or small case series focusing
only on clinical characteristics (5, 8–17). Recently, Trabelsi and
colleagues reported the epidemiological risk factors and clinical
outcomes of 55 cases of Y. lipolytica fungemia in Tunisia and pro-
vided some data on the in vitro susceptibility test results of the
isolates to a few antifungal drugs (6). However, details about the
correlative microbiological characteristics, including phenotypic
and genotypic identification and in vitro susceptibility test results
for newer antifungal drugs such as the echinocandins and po-
saconazole, were lacking in this larger case series. In this multi-
center, prospective surveillance study in China, we described the
epidemiological and clinical characteristics of 14 cases of Y. lipo-
lytica fungemia in correlation with the comparative performance
of several commonly employed phenotypic and genotypic identi-
fication methods, and we also described the in vitro susceptibility
of this emerging fungal pathogen to nine antifungal drugs, includ-
ing the newer azoles and echinocandins.
This study was approved by the Institutional Review Boards of
The University of Hong Kong/Hospital Authority Hong Kong
West Cluster and the Peking Union Medical College Hospital. As
described previously, the National China Hospital Invasive Fun-
gal Surveillance Net (CHIF-NET) study was a prospective, labo-
ratory-based, multicenter study of invasive yeast infections that
started on 1 August 2009 (18). The present study included all of
the Y. lipolytica blood culture isolates identified in the CHIF-NET
study from 1 August 2009 to 31 July 2012. These isolates were
identified as Y. lipolytica using the Vitek 2 YST identification (ID)
card system (bioMérieux, France) as previously described (19).
For isolates that had a single identification with a confidence value
of99.9%, multiple identifications, or no identification, internal
transcribed spacer (ITS) region sequencing was used for confir-
mation (19). Additionally, we compared the performance of the
API 20C Aux system (bioMérieux) and matrix-assisted laser de-
sorption ionization–time of flight mass spectrometry (MALDI-
TOF MS) for the identification of Y. lipolytica with that of the
Vitek 2 YST ID Card system (see the supplemental material).
Received 21 July 2015 Returned for modification 6 August 2015
Accepted 24 August 2015
Accepted manuscript posted online 26 August 2015
Citation Zhao Y, Chan JF-W, Tsang C-C, Wang H, Guo D, Pan Y, Xiao Y, Yue N,
Chen JH-K, Lau SK-P, Xu Y, Woo PC-Y. 2015. Clinical characteristics, laboratory
identification, and in vitro antifungal susceptibility of Yarrowia (Candida) lipolytica
isolates causing fungemia: a multicenter, prospective surveillance study. J Clin
Microbiol 53:3639–3645. doi:10.1128/JCM.01985-15.
Editor: D. W. Warnock
Address correspondence to Yingchun Xu, xycpumch@139.com, or
Patrick Chiu-Yat Woo, pcywoo@hku.hk.
Y.Z., J.F.-W.C., and C.-C.T. contributed equally to this article.
Supplemental material for this article may be found at http://dx.doi.org/10.1128
/JCM.01985-15.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
November 2015 Volume 53 Number 11 jcm.asm.org 3639Journal of Clinical Microbiology
T
A
B
LE
1
C
lin
ic
al
ch
ar
ac
te
ri
st
ic
s
of
13
pa
ti
en
ts
w
it
h
Y
ar
ro
w
ia
lip
ol
yt
ic
a
fu
n
ge
m
ia
a
C
as
e
Is
ol
at
e
Se
x/
A
ge
(y
r)
R
ea
so
n
fo
r
ad
m
is
si
on
(c
om
or
bi
di
ti
es
)
i.v
.c
at
h
et
er
s
(d
ay
s)
b
i.v
.
an
ti
bi
ot
ic
s
IC
U
Sp
ec
im
en
(s
)
T
re
at
m
en
t
O
u
tc
om
e
1
P
W
32
98
M
/6
5
R
oa
d
tr
af
fi
c
ac
ci
de
n
t
w
it
h
tr
au
m
at
ic
su
bd
u
ra
l
h
em
at
om
a,
m
u
lt
ip
le
fr
ac
tu
re
s,
an
d
ga
st
re
ct
om
y
P
V
C
(9
)
Y
es
N
o
B
lo
od
(p
er
ip
h
er
al
)
C
at
h
et
er
re
m
ov
al
an
d
i.v
.fl
u
co
n
az
ol
e
20
0
m
g
da
ily
D
is
ch
ar
ge
d
af
te
r
14
da
ys
of
h
os
pi
ta
liz
at
io
n
2
P
W
32
99
M
/4
6
P
os
to
pe
ra
ti
ve
fe
ve
r
(C
R
H
D
w
it
h
va
lv
u
la
r
re
pl
ac
em
en
t)
P
V
C
(1
1)
Y
es
Y
es
B
lo
od
(p
er
ip
h
er
al
)
C
at
h
et
er
re
m
ov
al
D
is
ch
ar
ge
d
af
te
r
20
da
ys
of
h
os
pi
ta
liz
at
io
n
3
P
W
33
00
M
/2
7
Fe
ve
r
w
it
h
h
yp
ot
en
si
on
(c
er
vi
ca
ls
pi
n
al
fr
ac
tu
re
w
it
h
pa
ra
pl
eg
ia
)
P
IC
C
(4
4)
Y
es
Y
es
B
lo
od
(P
IC
C
)
C
at
h
et
er
re
m
ov
al
T
ra
n
sf
er
re
d
to
an
ot
h
er
h
os
pi
ta
la
ft
er
55
da
ys
of
h
os
pi
ta
liz
at
io
n
4
P
W
33
01
M
/6
7
Is
ch
em
ic
st
ro
ke
w
it
h
h
em
or
rh
ag
ic
tr
an
sf
or
m
at
io
n
(E
SR
F)
C
V
C
(7
)
Y
es
Y
es
B
lo
od
(p
er
ip
h
er
al
an
d
C
V
C
)
C
at
h
et
er
re
m
ov
al
an
d
i.v
.
it
ra
co
n
az
ol
e
35
0
m
g
da
ily
D
is
ch
ar
ge
d
af
te
r
30
da
ys
of
h
os
pi
ta
liz
at
io
n
5
P
W
33
02
M
/7
3
R
ec
u
rr
en
t
pe
ri
to
n
it
is
(c
ar
ci
n
om
a
of
pa
n
cr
ea
s)
C
V
C
(4
0)
Y
es
Y
es
B
lo
od
(p
er
ip
h
er
al
an
d
C
V
C
)
C
at
h
et
er
re
m
ov
al
an
d
i.v
.
am
ph
ot
er
ic
in
B
25
m
g
D
is
ch
ar
ge
d
ag
ai
n
st
m
ed
ic
al
ad
vi
ce
af
te
r
45
da
ys
of
h
os
pi
ta
liz
at
io
n
6
P
W
33
03
M
/1
A
pn
ea
of
pr
em
at
u
ri
ty
P
V
C
(1
5)
Y
es
N
o
B
lo
od
(p
er
ip
h
er
al
)
C
at
h
et
er
re
m
ov
al
D
is
ch
ar
ge
d
af
te
r
16
da
ys
of
h
os
pi
ta
liz
at
io
n
7
P
W
33
04
M
/3
R
es
pi
ra
to
ry
di
st
re
ss
(c
on
ge
n
it
al
h
ea
rt
di
se
as
e)
C
V
C
(7
5)
Y
es
Y
es
B
lo
od
(p
er
ip
h
er
al
an
d
C
V
C
)
C
at
h
et
er
re
m
ov
al
an
d
or
al
fl
u
co
n
az
ol
e
15
0
m
g
da
ily
fo
r
12
da
ys
D
is
ch
ar
ge
d
af
te
r
4
m
o
of
h
os
pi
ta
liz
at
io
n
8
P
W
33
05
M
/6
3
B
ro
n
ch
ie
ct
ac
ti
c
ex
ac
er
ba
ti
on
(b
ro
n
ch
ie
ct
as
is
)
P
V
C
(6
)
Y
es
Y
es
B
lo
od
(p
er
ip
h
er
al
)
C
at
h
et
er
re
m
ov
al
an
d
i.v
.fl
u
co
n
az
ol
e
40
0
m
g
da
ily
fo
r
5
da
ys
D
ie
d
af
te
r
10
da
ys
of
h
os
pi
ta
liz
at
io
n
9
P
W
33
06
an
d
P
W
33
07
M
/7
5
In
tr
ac
er
eb
ra
lh
em
or
rh
ag
e
C
V
C
(3
0)
Y
es
Y
es
B
lo
od
(p
er
ip
h
er
al
an
d
C
V
C
,
re
sp
ec
ti
ve
ly
)
C
at
h
et
er
re
m
ov
al
an
d
i.v
.fl
u
co
n
az
ol
e
40
0
m
g
da
ily
fo
r
14
da
ys
D
ie
d
af
te
r
35
da
ys
of
h
os
pi
ta
liz
at
io
n
10
P
W
33
09
M
/4
3
P
n
eu
m
on
ia
(b
ra
in
st
em
de
at
h
)
P
V
C
(8
)
Y
es
N
o
B
lo
od
(p
er
ip
h
er
al
)
C
at
h
et
er
re
m
ov
al
D
is
ch
ar
ge
d
af
te
r
10
da
ys
of
h
os
pi
ta
liz
at
io
n
11
P
W
33
10
M
/4
5
In
te
st
in
al
ob
st
ru
ct
io
n
C
V
C
(3
8)
Y
es
Y
es
B
lo
od
(p
er
ip
h
er
al
an
d
C
V
C
)
C
at
h
et
er
re
m
ov
al
an
d
i.v
.fl
u
co
n
az
ol
e
40
0
m
g
da
ily
fo
r
27
da
ys
D
is
ch
ar
ge
d
af
te
r
49
da
ys
of
h
os
pi
ta
liz
at
io
n
12
P
W
33
11
M
/7
3
O
pe
n
sk
u
ll
fr
ac
tu
re
P
V
C
(3
1)
Y
es
Y
es
B
lo
od
(p
er
ip
h
er
al
)
C
at
h
et
er
re
m
ov
al
an
d
i.v
.fl
u
co
n
az
ol
e
20
0
m
g
da
ily
fo
r
37
da
ys
D
is
ch
ar
ge
d
af
te
r
2
m
o
of
h
os
pi
ta
liz
at
io
n
13
P
W
33
12
F/
82
R
ig
h
t
h
ip
fr
ac
tu
re
C
V
C
(3
8)
Y
es
Y
es
B
lo
od
(p
er
ip
h
er
al
an
d
C
V
C
)
C
at
h
et
er
re
m
ov
al
an
d
i.v
.fl
u
co
n
az
ol
e
40
0
m
g
da
ily
fo
r
40
da
ys
D
ie
d
af
te
r
45
da
ys
of
h
os
pi
ta
liz
at
io
n
a
T
h
e
cl
in
ic
al
da
ta
of
1
of
th
e
14
ca
se
s
in
th
is
st
u
dy
w
as
n
ot
av
ai
la
bl
e.
C
R
H
D
,c
h
ro
n
ic
rh
eu
m
at
ic
h
ea
rt
di
se
as
e;
C
V
C
,c
en
tr
al
ve
n
ou
s
ca
th
et
er
;E
SR
F,
en
d-
st
ag
e
re
n
al
fa
ilu
re
;F
,f
em
al
e;
i.v
.,
in
tr
av
en
ou
s;
IC
U
,i
n
te
n
si
ve
ca
re
u
n
it
;M
,m
al
e;
P
V
C
,p
er
ip
h
er
al
ve
n
ou
s
ca
th
et
er
;P
IC
C
,p
er
ip
h
er
al
ly
in
se
rt
ed
ce
n
tr
al
ca
th
et
er
.
b
D
u
ra
ti
on
of
in
tr
av
en
ou
s
ca
th
et
er
in
si
tu
be
fo
re
on
se
t
of
fu
n
ge
m
ia
.
Zhao et al.
3640 jcm.asm.org November 2015 Volume 53 Number 11Journal of Clinical Microbiology
A total of 14 cases of Y. lipolytica fungemia were identified
during the study period. The clinical characteristics of 13 patients
with available information are listed in Table 1. One patient (case
9) had two Y. lipolytica isolates identified from the blood cultures
obtained from the peripheral vein and central venous catheter
simultaneously. Twelve (92.3%) were males. Their median age
was 63 years (range, 1 to 82 years). Similar to previous reports, all
had risk factors for Y. lipolytica fungemia, including prior use of
broad-spectrum antibacterials (100.0%), prolonged hospitaliza-
tion and admission to the intensive care unit (84.6%), and intra-
vascular catheterization (100.0%). Seven (53.8%) had a central
venous catheter. The time interval between the setup of the intra-
venous catheter and the onset of fungemia was longer in those
with central venous catheters (mean, 38.9 days) than those with
peripheral venous catheters (mean, 13.3 days). All patients had
catheter removal after Y. lipolytica was isolated in blood culture,
but the use of antifungal treatment was variable. Four (30.8%) did
not receive any antifungal treatment, but they all survived after
catheter removal. The remaining nine (69.2%) received systemic
antifungal treatment, including fluconazole, itraconazole, and
amphotericin B for a range of 5 to 40 days. Three (23.1%) died
during hospitalization.
A major knowledge gap in the literature on Y. lipolytica cathe-
ter-related fungemia is the optimal management strategy. While
the clinical practice guideline for the management of candidiasis
by the Infectious Diseases Society of America recommends the use
of systemic antifungal treatment and catheter removal, some have
suggested that catheter removal alone might be sufficient in treat-
ing Y. lipolytica catheter-related infection (5, 14, 20). Catheter
removal without systemic antifungal treatment has rendered the
blood culture negative in some cases of Y. lipolytica catheter-re-
lated fungemia, including those involving neutropenic patients (5,
14). Y. lipolytica-associated suppurative thrombophlebitis may
also be successfully treated with catheter removal alone (5). Nearly
one-third (cases 2, 3, 6, and 10) of our patients did not receive
systemic antifungal treatment, but their fungemia resolved and
their clinical conditions improved after catheter removal. Our
data suggested that Y. lipolytica catheter-related infection may be
treated with catheter removal without systemic antifungal ther-
apy, provided that there is clinical improvement with resolution of
systemic and/or local symptoms and signs, microbiological docu-
mentation of clearance of fungemia, and an absence of persistent
infective foci such as endocarditis, abscess, and endophthalmitis.
Rapid and accurate identification is especially important for Y.
lipolytica, as the need and choice of systemic antifungal treatment
may differ between infections caused by Y. lipolytica and other
Candida spp. The Vitek 2 YST ID Card system identified all 15
(100.0%) isolates as Y. lipolytica with probabilities of 94.0% to
99.0% (see Table S1 in the supplemental material). None of the
isolates were identified as Y. lipolytica by the API 20C Aux system.
FIG 1 Dendrogram generated from the hierarchical cluster analysis (HCA) of the MALDI-TOF mass spectra of the case isolates, Y. lipolytica, and other Candida
spp. showing their relative relatedness.
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Nine (60.0%) were unidentifiable and the other six (40.0%) were
misidentified as Candida magnoliae, Candida zeylanoides, Can-
dida dubliniensis, or Sporobolomyces salmonicolor with probabili-
ties of 42.9% to 99.5%. In contrast, MALDI-TOF MS accurately
identified all (100.0%) isolates as Y. lipolytica with top match
scores of 1.884 to 2.250. Hierarchical cluster analysis of the
MALDI-TOF mass spectra of all 15 isolates also unambiguously
showed that they were clustered with other Y. lipolytica isolates
(Fig. 1).
For phylogenetic analysis, DNA extraction, PCR amplification,
and DNA sequencing of the ITS region for the isolates were per-
formed according to our previous publications (21–28) using the
primer pairs ITS1/ITS4 (29) for the ITS and NL1/NL4 (30) for the
25S nuclear ribosomal DNA (nrDNA) (see the supplemental ma-
terial). ITS and partial 25S nrDNA gene sequencing identified 14
and all 15 isolates as Y. lipolytica, respectively, confirming the re-
sults of the Vitek 2 YST ID card system and MALDI-TOF MS.
Since the electropherogram obtained from direct PCR product
sequencing for the ITS of isolate PW3301 was uninterpretable
where double or multiple peaks were observed frequently in the
sequence trace, the PCR product of the ITS of isolate PW3301 was
cloned into plasmids for another sequencing trial (see the supple-
mental material). Two of the four clones selected for sequencing
showed one ITS copy while the other two clones showed another
ITS copy, indicating the presence of intrastrain ITS heterogeneity
in the isolate PW3301. Pairwise alignment of the two ITS copies of
PW3301 showed that they differed by a single nucleotide insertion
of an A residue at the ITS2 region. This is the first report of intras-
train ITS heterogeneity in Y. lipolytica. Pairwise alignment also
showed that the ITS and 25S nrDNA sequences of the 15 isolates
possessed 98.3% to 99.3% and 99.8% to 100% identities to that of
Y. lipolytica strain CBS 6124T, respectively. Phylogenetic analyses
FIG 2 Phylogenetic trees showing the relationship between the 15 fungal isolates and other members of the Yarrowia clade. The trees were inferred from ITS and
25S nrDNA sequence data by the maximum likelihood method with the substitution models T92 (Tamura 3-parameter model) G (gamma-distributed rate
variation) and K2 (Kimura 2-parameter model)  G, respectively. The numbers of nucleotide positions of the trimmed, aligned sequences included for
phylogenetic analyses are 293 and 488, respectively. The trees were rooted using Candida blankii strains MUCL 29808T and NRRL Y-17068T, respectively. The
scale bars indicate the estimated numbers of substitutions per base. The numbers at the nodes, expressed in percentages, indicate levels of bootstrap support
calculated from 1,000 trees, and bootstrap values lower than 70 are not shown. All accession numbers (in parentheses) are given as cited in the DDBJ/ENA/
GenBank databases. The case isolates reported in this study are highlighted in bold type.
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based on the ITS and partial 25S nrDNA sequences showed that all
15 isolates were clustered withY. lipolyticaCBS 6124T (Fig. 2). The
low intraspecies sequence variability for ITS and 25S nrDNA forY.
lipolytica makes these two gene loci good DNA markers for the
identification of this fungus. In addition, ITS and 25S nrDNA
sequencing confirmed that isolates PW3306 and PW3307 ob-
tained from the same patient (case 9) were identical (100% se-
quence identities for both loci).
The susceptibilities of the isolates to nine different antifungal
drugs were tested by the broth microdilution method using Sen-
sititre YeastOne plates (Trek Diagnostic Systems, United King-
dom) according to the manufacturer’s instructions for Candida
spp. and Pfaller et al. (31). The MIC values and ranges were cal-
culated using WHONET 5.6 (World Health Organization Collab-
orating Center for Surveillance of Antibiotic Resistance, Boston,
MA, USA). The susceptibilities of the isolates to fluconazole and
voriconazole were also evaluated using Sensi-Disc antimicrobial
susceptibility test disks (BBL; BD Diagnostic Systems, Sparks,
MD, USA) by the disk diffusion method according to the Clinical
and Laboratory Standards Institute M44-A2 standard (32). We
performed antimicrobial susceptibility tests for only one of the
two isolates obtained in case 9 because they were identified to be
the same strain. All 14 (100.0%) Y. lipolytica isolates had MICs of
2.00 g/ml to voriconazole by the broth microdilution method
(Table 2). The MICs to the other azoles were less consistent, with
many of them having MICs of 4.00 g/ml to fluconazole, itra-
conazole, or posaconazole by the broth microdilution method.
The broth microdilution and disk diffusion methods demon-
strated that MICs and zone sizes were in general agreement with
each other for voriconazole and fluconazole, with the isolates hav-
ing lower MICs in the broth microdilution method also showing
larger zone sizes in the disk diffusion method. As for the other
antifungal agents, all 14 (100.0%) isolates had MICs of 2.00
g/ml to caspofungin, micafungin, anidulafungin, and ampho-
tericin B, whereas 10/14 (71.4%) isolates had MICs of 4.00
g/ml to flucytosine.
Fluconazole was the most commonly used antifungal drug in
the nine patients who received systemic antifungal treatment. This
was based on previous observations that most Y. lipolytica isolates
were susceptible to fluconazole in vitro (6, 8, 10). However, three
of our patients (cases 8, 9, and 13) who received fluconazole died
despite treatment and catheter removal. Their blood culture iso-
FIG 2 continued
Y. lipolytica Fungemia: Clinical-Laboratory Correlation
November 2015 Volume 53 Number 11 jcm.asm.org 3643Journal of Clinical Microbiology
lates had high MICs of 32 to256 g/ml to fluconazole. Impor-
tantly, all of these isolates also had MICs of1g/ml to itracona-
zole and2g/ml to posaconazole (Table 2). Thus, high MICs to
fluconazole might help to predict high MICs to itraconazole and
posaconazole, and infections caused by Y. lipolytica isolates with
high MICs to fluconazole should not be treated with itraconazole
and posaconazole. Our in vitro antifungal susceptibility data
showed that voriconazole, caspofungin, micafungin, anidulafun-
gin, and amphotericin B may be better treatment options.
Our study highlighted the need to establish standardized rec-
ommendations for determining in vitro antifungal susceptibility
for Y. lipolytica using different testing methods. The in vitro sus-
ceptibility to fluconazole and voriconazole by the broth microdi-
lution and disk diffusion methods differed markedly when the
recommended MICs and zone sizes for other Candida spp. were
used for interpretation. Y. lipolytica isolates with MICs of 16
g/ml and 1 g/ml against fluconazole and voriconazole, re-
spectively, had zone sizes corresponding to the resistant category
by the disk diffusion method. Furthermore, there are as yet no
interpretative criteria for posaconazole and amphotericin B for
Candida spp., although in general, an MIC of1g/ml is consid-
ered to inhibit most clinical isolates (33). The in vitro antifungal
susceptibility of more clinical isolates of Y. lipolytica with correla-
tion to the patients’ clinical response should be evaluated to deter-
mine the optimal breakpoints of this emerging fungal pathogen.
Nucleotide sequence accession numbers.
The ITS and partial 25S nrDNA sequences of the 15 Y. lipolytica
isolates have been deposited in the DDBJ/ENA/GenBank data-
bases with the accession numbers LC050530 to LC050560.
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